ANIP Q1 2018 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$46M+26.9% YoY

Gross Profit

$26M55.5% margin

Operating Income

$7M14.1% margin

Net Income

$2M4.8% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$21M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$418M

Total Liabilities

$238M

Stockholders' Equity

$180M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$37M	+26.9%
Gross Profit	$26M	$20M	+27.4%
Operating Income	$7M	$5M	+41.3%
Net Income	$2M	$1M	+96.1%

Revenue Segments

Sales of generic pharmaceutical products

$23M49%

Sales of branded pharmaceutical products

$17M35%

Royalties on sales of pharmaceutical products

$5M11%

Sales of contract manufactured products

$2M5%

Other revenues

$334,0001%